Ernexa Therapeutics Inc. (ERNA) shareholders
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.79−0.14 (-7.25%)
Close on Nov 12, 2026Market cap $2.92MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
9
9 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $2.00M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Charles Cherington | 10,791,335 | 34.70% | 13D (active) amendment | Feb 10, 2026 |
| John D. Halpern Joint filing with Katherine H. Halpern (9.99%) | 5,136,581 | 9.99% | 13G (passive) amendment | Oct 29, 2024 |
| Victoria Konar Joint filing with Shameek Konar (7.12%), Regolith Capital Investments LP (6.98%) | 558,531 | 7.12% | 13G (passive) amendment | Jun 30, 2025 |
| Freebird Investments LLC Joint filing with Freebird Partners LP (9.90%), Curtis Huff (9.90%) | 120,412 | 9.90% | 13G (passive) amendment | Feb 10, 2026 |
| Freebird Partners LP Joint filing with Freebird Investments LLC (7.00%), Curtis Huff (7.00%) | 119,015 | 7.00% | 13G (passive) amendment | Aug 5, 2026 |
| Shameek Konar Joint filing with Victoria Konar (9.70%), Regolith Capital Investments LP (9.70%) | 118,342 | 9.70% | 13G (passive) amendment | Feb 10, 2026 |
| Bleichroeder LP Joint filing with Bleichroeder Holdings LLC (6.86%), Andrew Gundlach (6.86%) | 80,000 | 6.86% | 13G (passive) | Mar 31, 2026 |
| Katherine H. Halpern Joint filing with John D. Halpern (5.60%) | 66,751 | 5.60% | 13G (passive) amendment | Feb 10, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ERNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 15,104 | – | $100.44K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 8,336 | – | $55.43K | New | 0.00% |
| Dauntless Investment Group, LLC | 6,000 | – | $39.90K | New | 0.03% |
| Vanguard Capital Management LLC | 5,684 | – | $37.80K | New | 0.00% |
| Tradewinds Capital Management, LLC | 361 | – | $2.40K | New | 0.00% |
| BlackRock, Inc. | 33 | – | $219 | New | 0.00% |
| Assetmark, Inc | 5 | – | $33 | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 1 | – | $7 | New | 0.00% |
| SBI Securities Co., Ltd. | 1 | – | $7 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ERNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 5,684 | – | $37.80K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 5,574 | – | $58.92K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 2,414 | – | $25.52K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1 | – | $7 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Sanjeev Luther | President and CEO, Director | – | Sep 1, 2026 |
| Sandra M. Gurrola | Sr. VP of Finance | 110 | Jul 7, 2025 |
| Robert J. Spiegel | Director | – | Sep 22, 2026 |
| James Arthur Bristol | Director | – | Sep 1, 2026 |
| William A. Wexler | Director | – | Sep 1, 2026 |
| David Polinsky | Director | 8,000 | Sep 1, 2026 |
| Peter Cicala | Director | – | Sep 1, 2026 |
| Elena Ratner | Director | – | Sep 1, 2026 |
| Charles Cherington | 10% owner | 6,779,440 | Feb 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Charles Cherington 10% owner | Feb 10, 2026 | Buy | +4,000,000 | $0.50 | $2.00M | 6,779,440 |
| Sandra M. Gurrola Sr. VP of Finance | Jun 21, 2025 | Option exercise | +30 | – | – | 110 |
| Charles Cherington 10% owner | Jun 9, 2025 | Buy | +21,241,163 | $0.10 | $2.12M | 41,659,743 |
| Charles Cherington 10% owner | Apr 2, 2025 | Buy | +3,768,397 | $0.10 | $376.84K | 20,401,602 |
| Charles Cherington 10% owner | Oct 29, 2024 | Buy | +261,756 | – | – | 818,221 |
| Charles Cherington 10% owner | Oct 29, 2024 | Buy | +5,420,823 | – | – | 12,245,589 |
| Charles Cherington 10% owner | Oct 29, 2024 | Buy | +1,237,762 | – | – | 6,824,766 |
| Charles Cherington 10% owner | Oct 29, 2024 | Buy | +4,768,783 | – | – | 5,587,004 |
| Charles Cherington 10% owner | Oct 29, 2024 | Conversion | +2,819,546 | $0.50 | $1.41M | 16,628,123 |
| Charles Cherington 10% owner | Oct 29, 2024 | Buy | +1,562,988 | – | – | 13,808,577 |
| Charles Cherington 10% owner | Sep 24, 2024 | Buy | +261,756 | – | – | 818,221 |
| Charles Cherington 10% owner | Sep 24, 2024 | Buy | +4,768,783 | – | – | 5,587,004 |
| Charles Cherington 10% owner | Sep 24, 2024 | Buy | +1,237,762 | – | – | 6,824,766 |
| Charles Cherington 10% owner | Sep 24, 2024 | Buy | +5,420,823 | – | – | 12,245,589 |
| Charles Cherington 10% owner | Sep 24, 2024 | Buy | +1,562,988 | – | – | 13,808,577 |
| Sandra M. Gurrola Sr. VP of Finance | Jun 21, 2024 | Tax withholding | −180 | $1.94 | $349 | 1,185 |
| Sandra M. Gurrola Sr. VP of Finance | Jun 21, 2024 | Option exercise | +437 | – | – | 1,365 |
| Sandra M. Gurrola Vice President of Finance | Jun 21, 2023 | Option exercise | +438 | – | – | 1,107 |
| Sandra M. Gurrola Vice President of Finance | Jun 21, 2023 | Tax withholding | −179 | $2.48 | $444 | 928 |
| Nicholas Jason Singer Director | Dec 2, 2022 | Buy | +70,822 | $3.28 | $232.30K | 121,822 |
| Nicholas Jason Singer Director | Dec 2, 2022 | Buy | +212,464 | $3.28 | $696.88K | 266,214 |
| Charles Cherington Director, 10% owner | Dec 2, 2022 | Buy | +261,756 | $3.28 | $858.56K | 556,465 |
| John D. Halpern 10% owner | Dec 2, 2022 | Buy | +335,920 | $3.28 | $1.10M | 450,961 |
| Roger Sidhu Chief Medical Officer | Sep 20, 2022 | Option exercise | +20,163 | – | – | 20,163 |
| Kevin DAmour Chief Scientific Officer | Jun 28, 2022 | Tax withholding | −6,077 | $0.55 | $3.34K | 11,496 |
| Kevin DAmour Chief Scientific Officer | Jun 28, 2022 | Option exercise | +17,573 | – | – | 17,573 |
| Sandra M. Gurrola Vice President of Finance | Jun 21, 2022 | Tax withholding | −3,586 | $0.48 | $1.72K | 13,367 |
| Sandra M. Gurrola Vice President of Finance | Jun 21, 2022 | Option exercise | +8,750 | – | – | 16,953 |
| George P. Denny Iii 10% owner | Jul 14, 2021 | Buy | +1 | $11.99 | $12 | 3 |
| George P. Denny Iii 10% owner | Jul 9, 2021 | Buy | +1 | $14.11 | $14 | 2 |
| George P. Denny Iii 10% owner | Jul 8, 2021 | Buy | +1 | $14.35 | $14 | 1 |
| George P. Denny Iii 10% owner | Jul 6, 2021 | Sale | −75,000 | $16.06 | $1.20M | 4,775,117 |
| Charles Cherington Director, 10% owner | Jun 17, 2021 | Sale | −198,000 | $15.74 | $3.12M | 5,896,101 |
| Charles Cherington Director, 10% owner | Jun 17, 2021 | Sale | −2,000 | $16.30 | $32.60K | 5,894,101 |
| Charles Cherington Director, 10% owner | Jun 16, 2021 | Sale | −200,000 | $15.73 | $3.15M | 6,094,101 |
| Charles Cherington Director | Jun 1, 2021 | Other | +92 | – | – | 5,894,193 |
| Allen Wolff Former Director and CEO | Mar 24, 2021 | Tax withholding | −9,944 | $2.67 | $26.55K | 128,520 |
| Sandra M. Gurrola Former SVP of Finance | Mar 24, 2021 | Tax withholding | −6,094 | $2.67 | $16.27K | 21,617 |
| Sandra M. Gurrola SVP of Finance | Mar 19, 2021 | Tax withholding | −116 | $3.53 | $409 | 27,711 |
| Allen Wolff CEO, Director | Mar 19, 2021 | Tax withholding | −207 | $3.53 | $731 | 138,464 |
| Sandra M. Gurrola SVP of Finance | Feb 19, 2021 | Tax withholding | −115 | $4.81 | $553 | 27,827 |
| Allen Wolff CEO, Director | Feb 19, 2021 | Tax withholding | −207 | $4.81 | $996 | 138,671 |
| Sandra M. Gurrola SVP of Finance | Jan 19, 2021 | Tax withholding | −1,400 | $2.55 | $3.57K | 27,942 |
| Allen Wolff CEO, Director | Jan 19, 2021 | Tax withholding | −2,987 | $2.55 | $7.62K | 138,878 |
| Allen Wolff CEO, Director | Dec 19, 2020 | Tax withholding | −170 | $2.17 | $369 | 141,865 |
| Sandra M. Gurrola SVP of Finance | Dec 19, 2020 | Tax withholding | −100 | $2.17 | $217 | 29,342 |
| Sandra M. Gurrola SVP of Finance | Nov 20, 2020 | Tax withholding | −98 | $1.88 | $184 | 29,442 |
| Allen Wolff CEO, Director | Nov 20, 2020 | Tax withholding | −170 | $1.88 | $320 | 142,035 |
| Sandra M. Gurrola SVP of Finance | Oct 21, 2020 | Tax withholding | −1,178 | $2.05 | $2.41K | 29,540 |
| Allen Wolff CEO, Director | Oct 21, 2020 | Tax withholding | −2,453 | $2.05 | $5.03K | 142,205 |
| Allen Wolff CEO, Director | Sep 22, 2020 | Tax withholding | −170 | $1.99 | $338 | 144,658 |
| Sandra M. Gurrola SVP of Finance | Sep 22, 2020 | Tax withholding | −97 | $1.99 | $193 | 30,718 |
| Allen Wolff CEO, Director | Aug 25, 2020 | Tax withholding | −170 | $2.62 | $445 | 144,828 |
| Sandra M. Gurrola SVP of Finance | Aug 25, 2020 | Tax withholding | −98 | $2.62 | $257 | 30,815 |
| Robert S. Ellin 10% owner | Aug 13, 2020 | Sale | −170,900 | $5.33 | $910.90K | 16,194 |
| Robert S. Ellin 10% owner | Aug 13, 2020 | Sale | −156,750 | $5.79 | $907.58K | 421 |
| Sandra M. Gurrola SVP of Finance | Jul 28, 2020 | Tax withholding | −1,178 | $1.85 | $2.18K | 30,913 |
| Allen Wolff CEO, Director | Jul 28, 2020 | Tax withholding | −2,453 | $1.85 | $4.54K | 144,998 |
| Sandra M. Gurrola SVP of Finance | Jun 29, 2020 | Tax withholding | −97 | $3.15 | $306 | 32,091 |
| Allen Wolff CEO, Director | Jun 29, 2020 | Tax withholding | −170 | $3.15 | $536 | 147,451 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
2.0
At 0M shares a day
Change since last report
+67.3%
From 0M shares
Short volume, 20 days
33.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ernexa Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,369 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?